Subtype
Liver Neoplasm
CI-CAN-00001077Explore in graph →
Non-malignant929 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001077Explore in graph →
Clinical trials
4,334 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07077798 | Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection | not yet recruiting | N/A | 234 | Wan-Guang ZhangOTHER | 0 | Jul 22, 2025 | clinicaltrials |
| NCT07078292 | The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world Study | not yet recruiting | — | 400 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 22, 2025 |
| clinicaltrials |
| NCT07078305 | Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment | not yet recruiting | Phase 2 | 134 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 22, 2025 | clinicaltrials |
| NCT03844399 | (3D) Ultrasound Imaging Liver and Kidney | recruiting | — | 40 | Western University, CanadaOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07075419 | JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure | not yet recruiting | Phase 1 / Phase 2 | 10 | West China HospitalOTHER | 0 | Jul 20, 2025 | clinicaltrials |
| NCT06248528 | Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy. | active not recruiting | N/A | 1,076 | Chen XiaopingOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06391749 | Clinical Validation of an MCED Test in Symptomatic Populations (K-ACCELERATE)(K-ACCELERATE) | enrolling by invitation | — | 1,000 | Gene SolutionsINDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07064668 | Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study | not yet recruiting | Phase 2 | 300 | Tongji HospitalOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT07063771 | Safety and Clinical Efficacy of Histotripsy for Liver Cancers Adjacent to Major Intrahepatic Vessels | not yet recruiting | N/A | 20 | National Taiwan University HospitalOTHER | 0 | Jul 14, 2025 | clinicaltrials |
| NCT07063888 | A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 66 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05810402 | Liver Cancer and Immunotherapy in the Liquid Biopsy Era(LILIPSY) | recruiting | N/A | 60 | University Hospital, MontpellierOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT07058649 | Downstaging Prediction Model for HCC | not yet recruiting | — | 369 | Beijing Tsinghua Chang Gung HospitalOTHER | 0 | Jul 10, 2025 | clinicaltrials |
| NCT06842563 | Hepatocellular Carcinoma 3 Gene Methylation Combination Detection Kit (PCR Fluorescent Probe Method) Multicenter Clinical Trial | active not recruiting | — | 900 | Singlera Genomics Inc.INDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT07056270 | Development of a Set of Auxiliary Decision-making System for the Perioperative Period of Hepatectomy Based on Static CT and Artificial Intelligence. | not yet recruiting | — | 500 | Tongji HospitalOTHER | 0 | Jul 9, 2025 | clinicaltrials |
| NCT07053488 | CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection | recruiting | Phase 1 / Phase 2 | 90 | AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLCOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT07055048 | The Diagnostic Efficacy and Lesion Detection Advantages of 18F-FDG PET/Contrast-enhanced MRI in Malignant Liver Lesions | not yet recruiting | — | 60 | Shanghai East HospitalOTHER | 0 | Jul 8, 2025 | clinicaltrials |
| NCT05797805 | A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 178 | Iterion TherapeuticsINDUSTRY | 2 | Jul 4, 2025 | clinicaltrials |
| NCT07052448 | The Efficacy of Sequential RT After Triple Therapy for uHCC | enrolling by invitation | — | 35 | Fujian Provincial HospitalOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT07047586 | Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab(LEAF-01) | recruiting | Phase 2 | 146 | Fudan UniversityOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06954467 | JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 72 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06999174 | Multiparametric MRI for Characterization of Hepatocellular Carcinoma | recruiting | — | 128 | University Hospital MuensterOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07046832 | Clinical Evaluation of an Augmented Reality Intraprocedural Needle Guidance Platform for Soft Tissue Biopsy | enrolling by invitation | N/A | 104 | MediView XR, Inc.INDUSTRY | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07048665 | Effectiveness of Trans-Arterial Chemo Embolization for Hepatocellular Carcinoma on Follow-Up CT Triphasic Liver | active not recruiting | — | 60 | Superior UniversityOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07045558 | HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC | not yet recruiting | — | 28 | RenJi HospitalOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT07042841 | AI-Driven Quantitative Decision and Surgical Planning System for Liver Cancer | enrolling by invitation | — | 300 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT06194461 | LTFU for All Cell and Gene Therapy Studies(LOCUS) | not yet recruiting | — | 64 | AstraZenecaINDUSTRY | 4 | Jun 27, 2025 | clinicaltrials |
| NCT05451043 | Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) | recruiting | Phase 2 | 62 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06643208 | D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC | recruiting | — | 37 | Fujian Provincial HospitalOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07038863 | Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France(Mondelta) | not yet recruiting | N/A | 2,000 | Hospices Civils de LyonOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07018518 | PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma | recruiting | Phase 1 | 25 | Chinese PLA General HospitalOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT04348838 | Prospective Cohort of Patients With Hepatocellular Carcinoma in France(CHIEF) | recruiting | — | 5,000 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT07010198 | Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City | recruiting | — | 4,500 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT07010588 | Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk(SHORT) | not yet recruiting | N/A | 1,389 | Peking University People's HospitalOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06994130 | Seravue Validation Study for Hepatocellular Carcinoma (HCC) Diagnosis(Seravue) | not yet recruiting | — | 1,392 | ImCare BiotechINDUSTRY | 1 | Jun 4, 2025 | clinicaltrials |
| NCT07001592 | Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors(RIOT3) | recruiting | Phase 1 | 18 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06312826 | Abbreviated MRI Using Gadoxetic Acid Versus Ultrasonography for Surveillance of Early-stage HCC in Patients at High Risk | active not recruiting | N/A | 806 | Asan Medical CenterOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06994572 | Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 1 | 141 | Captor Therapeutics S.A.INDUSTRY | 0 | May 29, 2025 | clinicaltrials |
| NCT06995105 | Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 30 | Zhejiang UniversityOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT04791735 | Value of the Laparoscopic Approach in the Surgical Management of Resectable Hepatocellular Carcinoma(LapCHC) | active not recruiting | N/A | 252 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06990620 | TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC(TACE HCC) | not yet recruiting | Phase 1 | 56 | Fudan UniversityOTHER | 0 | May 25, 2025 | clinicaltrials |
| NCT04941287 | Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer | active not recruiting | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | May 23, 2025 | clinicaltrials |
| NCT06741020 | Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma(HAICI) | recruiting | Phase 1 / Phase 2 | 10 | Zhejiang Cancer HospitalOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06984718 | A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC | not yet recruiting | Phase 2 | 120 | AkesoINDUSTRY | 0 | May 22, 2025 | clinicaltrials |
| NCT05660213 | A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer | not yet recruiting | — | 750 | Fudan UniversityOTHER | 0 | May 20, 2025 | clinicaltrials |
| NCT06977399 | The Application Value of Spectral CT in the Accurate Staging of Liver Cancer | not yet recruiting | N/A | 150 | Yunnan Cancer HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06978933 | FGF19 Overexpression Combination Unified Study in HCC-19(FOCUS-19) | recruiting | Phase 2 | 42 | RenJi HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06251115 | Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced HCC | recruiting | N/A | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT05657249 | Alternative Surveillance Program for Patients With High Risk Group of HCC | active not recruiting | N/A | 199 | Seoul National University HospitalOTHER | 1 | May 15, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jul 22, 2025source: clinicaltrials